GRM5 and melanoma: However, GRM1 agonist, L-quisqualate, was the only compound tested that lowered xCT expression in melanoma cells (data not shown) suggesting that other possible effectors of xCT may be present other than GRM1 such as GRM5 or AMPA receptors.